• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19.先前感染过新冠病毒的免疫功能低下血液学患者接种新冠病毒疫苗后的加强免疫效果。
Blood Adv. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326.
2
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.西班牙血液学和输血学会关于肿瘤血液病患者 SARS-CoV-2 疫苗接种的专家共识意见。
Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20.
3
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.中国广东奥密克戎 BA.2 感染突破性感染用灭活 COVID-19 疫苗加强接种的效果：一项队列研究。
Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023.
4
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.SARS-CoV-2 S1 亚单位加强疫苗在老年小鼠中引发强烈的体液免疫应答。
Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10.
5
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.面对奥密克戎变异株——疫苗对轻症和重症 COVID-19 的保护效果如何？一项实时系统评价的第三次中期分析。
Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. eCollection 2022.
6
Pediatric hematology/oncology physician and nurse practitioner attitudes towards the COVID-19 vaccines: A qualitative study.儿科血液学/肿瘤学医师和护士从业者对 COVID-19 疫苗的态度：一项定性研究。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2048560. doi: 10.1080/21645515.2022.2048560. Epub 2022 Mar 28.
7
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
8
Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.妊娠期 2019 年冠状病毒病（COVID-19）疫苗接种、严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染史和疫苗加强剂与分娩时母婴抗体水平的关系。
Obstet Gynecol. 2022 Mar 1;139(3):373-380. doi: 10.1097/AOG.0000000000004693.
9
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.接种疫苗的免疫功能低下血液系统疾病患者感染 SARS-CoV-2 的死亡率低。
Intern Med J. 2022 Dec;52(12):2172-2175. doi: 10.1111/imj.15954. Epub 2022 Nov 27.
10
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.

引用本文的文献

1
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.血液系统疾病患者和细胞治疗接受者的奥密克戎SARS-CoV-2感染管理及结局
Front Oncol. 2024 Jun 19;14:1389345. doi: 10.3389/fonc.2024.1389345. eCollection 2024.
2
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).两剂BNT162b2 mRNA新冠疫苗接种后血液系统疾病患者的体液和细胞免疫反应：一项单中心前瞻性观察研究（NCT05074706）
EJHaem. 2022 Aug 30;3(4):1201-8. doi: 10.1002/jha2.544.
3
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.血液系统疾病患者的 SARS-CoV-2 疫苗反应和突破性感染率。
J Hematol Oncol. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7.

本文引用的文献

1
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
2
Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.异基因造血干细胞移植受者使用紧急授权的 SARS-CoV2 疫苗的安全性和耐受性。
Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6. doi: 10.1016/j.jtct.2021.07.008. Epub 2021 Jul 15.
3
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.异基因造血干细胞移植受者第二次接种BNT162b2后的抗体反应。
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.多发性骨髓瘤患者对 BNT162b2 mRNA COVID19 疫苗的体液反应率和反应预测因子。
Br J Haematol. 2021 Oct;195(2):186-193. doi: 10.1111/bjh.17608. Epub 2021 Jul 1.
6
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.BNT162b2 COVID-19 疫苗在血液恶性肿瘤患者中的有效性显著降低。
Am J Hematol. 2021 Oct 1;96(10):1195-1203. doi: 10.1002/ajh.26284. Epub 2021 Jul 14.
7
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
8
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第三剂新冠病毒疫苗的安全性和免疫原性：病例系列
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
9
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
10
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19.

作者信息

Piñana José Luis, Garcia-Sanz Ramon, Martino Rodrigo, Garcia-Roa María, Martin-Martin Gabriel Andrés, Risco-Gálvez Irene, Tormo Mar, Martinez-Barranco Pilar, Marcos-Corrales Sara, Calabuig Marisa, Conesa Venancio, Teruel Anabel, Ruiz-Pérez Sara, Solano Carlos, Navarro David, Cedillo Ángel, Sureda Anna

机构信息

Hematology Department and.

Fundación INCLIVA, Instituto de Investigación Sanitaria, Hospital Clínico Universitario de Valencia, Valencia, Spain.

出版信息

Blood Adv. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326.

DOI:10.1182/bloodadvances.2021006326
PMID:34905620
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8674106/
Abstract
摘要